Loading...
000538 logo

Yunnan Baiyao Group Co.,LtdSZSE:000538 Stock Report

Market Cap CN¥98.3b
Share Price
CN¥54.92
CN¥68.33
19.6% undervalued intrinsic discount
1Y-3.4%
7D-2.7%
Portfolio Value
View

Yunnan Baiyao Group Co.,Ltd

SZSE:000538 Stock Report

Market Cap: CN¥98.3b

000538 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

US$21.53
69.1% undervalued intrinsic discount
Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

Yunnan Baiyao Group Co.,Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Yunnan Baiyao GroupLtd
Historical stock prices
Current Share PriceCN¥54.92
52 Week HighCN¥60.69
52 Week LowCN¥53.90
Beta0.27
1 Month Change-3.14%
3 Month Change-4.19%
1 Year Change-3.45%
3 Year Change-1.58%
5 Year Change-31.75%
Change since IPO13,980.28%

Recent News & Updates

Recent updates

Shareholder Returns

000538CN PharmaceuticalsCN Market
7D-2.7%-2.8%2.6%
1Y-3.4%13.9%31.6%

Return vs Industry: 000538 underperformed the CN Pharmaceuticals industry which returned 13.9% over the past year.

Return vs Market: 000538 underperformed the CN Market which returned 31.6% over the past year.

Price Volatility

Is 000538's price volatile compared to industry and market?
000538 volatility
000538 Average Weekly Movement2.0%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement6.4%
10% most volatile stocks in CN Market10.2%
10% least volatile stocks in CN Market4.1%

Stable Share Price: 000538 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 000538's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19029,286Ming Dongwww.yunnanbaiyao.com.cn

Yunnan Baiyao Group Co.,Ltd engages in the sale of pharmaceuticals, medicinal materials, health and daily chemical products in China. The company offers health products; traditional Chinese medicine used for pain management and anti-inflammation, including the Yunnan Baiyao aerosol, Yunnan Baiyao ointment, and Yunnan Baiyao band-aid; generic drugs and natural specialty medicines in various areas, such as physical fitness, respiratory ailments, cardiovascular health, gynecology, pediatrics, and others; medical devices; tea products; and pharmaceutical supply chain service solutions. Yunnan Baiyao Group Co., Ltd.

Yunnan Baiyao Group Co.,Ltd Fundamentals Summary

How do Yunnan Baiyao GroupLtd's earnings and revenue compare to its market cap?
000538 fundamental statistics
Market capCN¥98.31b
Earnings (TTM)CN¥5.15b
Revenue (TTM)CN¥41.19b
19.0x
P/E Ratio
2.4x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
000538 income statement (TTM)
RevenueCN¥41.19b
Cost of RevenueCN¥29.28b
Gross ProfitCN¥11.90b
Other ExpensesCN¥6.75b
EarningsCN¥5.15b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Apr 30, 2026

Earnings per share (EPS)2.89
Gross Margin28.90%
Net Profit Margin12.51%
Debt/Equity Ratio0.7%

How did 000538 perform over the long term?

See historical performance and comparison

Dividends

4.7%
Current Dividend Yield
55%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/10 08:25
End of Day Share Price 2026/04/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Yunnan Baiyao Group Co.,Ltd is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhe SunBofA Global Research
Pei ChengChina Galaxy Securities Co., Ltd.
Yanyin ZhuChina International Capital Corporation Limited